Bharvin Patel

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

B. Wood, S. Riddell, A. Salter, 2019, Blood.

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.

Suzanne F. Jones, J. Bendell, H. Burris, 2016, European journal of cancer.

Targeting Apoptosis Pathways for Cancer Therapy

B. Patel, Bharvin Patel, 2005 .

Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling

P. Hipskind, Hong Gao, K. Credille, 2011 .

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Shobha N. Bhattachar, R. Campbell, Y. Qian, 2019, Molecular Cancer Therapeutics.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

D. Timm, R. Walgren, P. Ebert, 2018, Oncotarget.

Notch Pathway Is Activated via Genetic and Epigenetic Alterations and Is a Therapeutic Target in Clear Cell Renal Cancer*

K. Pradhan, J. Greally, A. Verma, 2016, The Journal of Biological Chemistry.

Antisense Inhibition of Survivin Expression as a Cancer Therapeutic

P. Iversen, G. Sandusky, N. Stamm, 2011, Molecular Cancer Therapeutics.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

J. Soria, C. Massard, D. Sarker, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.